|
罗沙司他胶囊联合康复运动训练对维持性血液透析肾性贫血患者血红蛋白及炎性反应的影响
|
Abstract:
目的:探讨罗沙司他胶囊联合康复运动训练对维持性血液透析肾性贫血患者的血红蛋白水平及炎性反应的影响。方法:本研究采用随机对照试验,纳入了120例维持性血液透析的肾性贫血患者,随机分为两组:治疗组和对照组。治疗组在常规血液透析基础上给予罗沙司他胶囊治疗,并结合康复运动训练;对照组仅进行常规血液透析治疗。两组均治疗12周,观察并比较治疗前后血红蛋白水平、铁代谢指标、炎症因子(C反应蛋白、肿瘤坏死因子α)的变化。结果:治疗12周后,治疗组的血红蛋白水平较基线有显著提升,且提升幅度大于对照组(P < 0.05)。治疗组的铁代谢指标,包括血清铁、铁蛋白和转铁蛋白饱和度,均较对照组有显著改善(P < 0.05)。炎症因子水平在治疗组中显著下降,而对照组变化不显著(P < 0.05)。结论:罗沙司他胶囊联合康复运动训练可有效提高维持性血液透析肾性贫血患者的血红蛋白水平,改善铁代谢,降低炎症反应,对改善患者的贫血状况和整体健康状况具有积极作用。
Objective: To investigate the effects of Rosuvastatin capsules combined with rehabilitation exercise training on hemoglobin levels and inflammatory reactions in maintenance hemodialysis patients with renal anemia. Methods: This study used a randomized controlled trial and included 120 patients with renal anemia undergoing maintenance hemodialysis. They were randomly divided into two groups: the treatment group and the control group. The treatment group was given Rosuvastatin capsules on the basis of routine hemodialysis, combined with rehabilitation exercise training; The control group only received routine hemodialysis treatment. Both groups were treated for 12 weeks, and changes in hemoglobin levels, iron metabolism indicators, and inflammatory factors (C-reactive protein, tumor necrosis factor alpha) were observed and compared before and after treatment. Results: After 12 weeks of treatment, the hemoglobin level in the treatment group significantly increased compared to baseline, and the increase was greater than that in the control group (P < 0.05). The iron metabolism indicators of the treatment group, including serum iron, ferritin, and transferrin saturation, were significantly improved compared to the control group (P < 0.05). The levels of inflammatory factors significantly decreased in the treatment group, while there was no significant change in the control group (P < 0.05). Conclusion: The combination of Rosuvastatin capsules and rehabilitation exercise training can effectively improve the hemoglobin level, iron metabolism, and inflammatory response in maintenance hemodialysis patients with renal anemia. It has a positive effect on improving the anemia status and overall health of patients.
[1] | 张爱丽, 侯旗旗, 韩全乐, 等. 中国北方人群心房颤动与新发慢性肾脏病发病风险的相关性研究[J]. 中国全科医学, 2023, 26(36): 4521-4526. |
[2] | Mahar, M.K., Yang, S., et al. (2024) Integrated Population Pharmacokinetics of Daprodustat in Patients with Chronic Kidney Disease with Anemia. Clinical Pharmacokinetics, 63, 1327-1341. https://doi.org/10.1007/s40262-024-01417-9 |
[3] | 秦雪艳, 谢晓恬. RPL35A基因突变相关先天性纯红细胞再生障碍性贫血诊治研究[J]. 世界临床药物, 2024, 45(7): 763-768. |
[4] | Li, X., Jiang, S., Gu, X., et al. (2024) Assessment of the Safety of Roxadustat for Cardiovascular Events in Chronic Kidney Disease-Related Anemia Using Meta-Analysis and Bioinformatics. Frontiers in Pharmacology, 15, Article 1380326. https://doi.org/10.3389/fphar.2024.1380326 |
[5] | Brito, D.S.J., Borges, A.N., Reis, V.D.M.C.D., et al. (2024) Effects of Intradialytic Bicycle Ergometer Exercise on Transcription Factors NF-ĸB and Nrf2 in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial. Journal of Bodywork & Movement Therapies, 40, 1492-1501. https://doi.org/10.1016/j.jbmt.2024.08.003 |
[6] | 董宗瑛, 第加美, 袁玲, 等. 生血宁联合罗沙司他治疗慢性肾脏病合并肾性贫血对贫血指标及血清铁、铁蛋白的影响[J]. 中国药物应用与监测, 2024, 21(4): 336-339. |
[7] | 张贤英, 居艳开. 血液透析联合血液灌流治疗对慢性肾衰竭患者的临床疗效及炎症因子和钙磷代谢的影响[J]. 中国药物经济学, 2024, 19(S1): 101-103. |
[8] | 苏鑫, 顾恒琼, 索继江, 等. 常见炎症因子诊断慢性肾功能不全并发肺部感染的临床价值[J]. 中华医院感染学杂志, 2023, 33(2): 189-192. |